Cyanotech Reports Slight Decline in Net Sales but Improved Gross Profit in Q1 FY2025

Cyanotech Corporation reported its financial results for the first quarter of fiscal year 2025, ending June 30, 2025, revealing a slight decline in net sales to $5.82 million, down from $5.90 million in the same period last year. The company achieved a gross profit of $1.77 million, an increase from $1.48 million year-over-year, primarily due to a reduction in the cost of sales, which decreased from $4.42 million to $4.05 million. Despite the decrease in revenue, the company reported a reduced net loss of $926,000, or $0.13 per share, compared to a net loss of $1.20 million, or $0.17 per share, in the prior year.

In terms of operational metrics, Cyanotech's total current assets remained relatively stable at $10.52 million as of June 30, 2025, compared to $10.55 million at the end of the previous quarter. However, the company experienced an increase in current liabilities, which rose to $10.78 million from $10.24 million, leading to a negative working capital deficit of $255,000. The company’s cash position improved slightly, with cash on hand increasing to $383,000 from $257,000 in the previous quarter.

Strategically, Cyanotech has made several organizational changes, including the hiring of a new Head of Sales to enhance its eCommerce presence and optimize marketing efforts. The company continues to focus on cost-saving initiatives, which include reducing production in line with customer demand and maintaining a lower headcount through attrition and furloughs. These measures are part of a broader strategy to address ongoing cash flow challenges and improve operational efficiency.

Cyanotech's product lines, which include Hawaiian Spirulina Pacifica and BioAstin Hawaiian Astaxanthin, continue to face competitive pressures, with significant customer concentration risk as three customers accounted for 62% of accounts receivable as of June 30, 2025. The company is actively working to diversify its customer base and expand its market share, particularly in the dietary supplements sector. As of the latest report, the company has not made any significant acquisitions but remains focused on enhancing its product offerings and market reach.

Looking ahead, Cyanotech's management expressed cautious optimism regarding its operational plan, which aims to generate sufficient cash flows to meet financing requirements. However, the company acknowledged the uncertainty surrounding its ability to comply with debt covenants and the potential for future covenant violations. The company is currently evaluating the impact of recent tax legislation on its financial position and is committed to executing its strategic initiatives to improve its financial health in the coming quarters.